{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-033247","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.246435+00:00","generated_at":"2026-06-04T23:07:38.760437+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioXcel Q4 net loss narrows to $22.3M; cash runs only to mid-2024; FDA requires more TRANQUILITY data","bullets":["Net loss $22.3M Q4 2023 vs $54.8M Q4 2022; full-year net loss $179.0M vs $165.8M.","Cash and equivalents $65.2M at Dec 31, 2023, expected to fund operations only through mid-2024.","FDA requires additional Phase 3 efficacy/safety data for BXCL501 in care facilities for Alzheimer's agitation (TRANQUILITY); at-home trial re-evaluated.","SERENITY program: FDA meeting supports Phase 3 trial amendment for at-home use of 120 mcg BXCL501 for bipolar/schizophrenia agitation.","Initiated formal process to assess strategic options for OnkosXcel Therapeutics subsidiary."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-033247","json":"https://secwatch.observer/filing/0001104659-24-033247.json","markdown":"https://secwatch.observer/filing/0001104659-24-033247.md","text":"https://secwatch.observer/filing/0001104659-24-033247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924033247/0001104659-24-033247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924033247/tm248359d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:07:38.760437+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d93a10d58e974659b21bb18472f677cac33b551f","claim":"BioXcel Therapeutics, Inc. reported the fourth quarter and full year 2023 results: revenue Net revenue from IGALMI was $376,000 for the fourth quarter of 2023.","evidence_excerpt":"Net revenue from IGALMI was $376,000 for the fourth quarter of 2023, compared to $238,000 for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924033247/0001104659-24-033247-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year 2023"},{"label":"Revenue","value":"Net revenue from IGALMI was $376,000 for the fourth quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}